Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,548 shares of the medical equipment provider’s stock, valued at approximately $502,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DV Equities LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth about $25,000. Monetary Solutions Ltd bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $30,000. Gen Wealth Partners Inc acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $32,000. Finally, Grove Bank & Trust raised its holdings in shares of Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.28% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZBH. BMO Capital Markets initiated coverage on shares of Zimmer Biomet in a report on Wednesday, July 8th. They set a “market perform” rating and a $95.00 target price for the company. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Wells Fargo & Company dropped their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $100.70.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $91.18 on Friday. The firm has a market capitalization of $17.64 billion, a P/E ratio of 23.68, a price-to-earnings-growth ratio of 2.76 and a beta of 0.46. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The firm’s fifty day moving average price is $87.17 and its two-hundred day moving average price is $89.83. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.